Biomarker-Driven Lung Cancer

Martin Dietrich, MD, PhD, discusses the role MET alterations play as oncogenic drivers of non–small cell lung cancer.

During a live virtual event, Martin Dietrich, MD, PhD, discusses how to address switching treatments in response to detection of a MET gene biomarker.

During a live virtual event, Martin Dietrich, MD, PhD, discusses management of toxicities and adverse events of MET inhibitors in non–small cell lung cancer.

At a live virtual event, Martin Dietrich, MD, PhD, discusses treatment options for a patient with non–small cell lung cancer when molecular testing shows a MET exon 14 skipping mutation.

Giuseppe Giaccone, MD, PhD, discusses the results of the VISION trial of tepotinib in patients with non–small cell lung cancer.

At a live virtual event, Martin Dietrich, MD, PhD, discusses how to approach biopsies and molecular testing in coordination with pathologists and testing services for patients with non–small cell lung cancer.

Bemcentinib is currently being studied in combination with pembrolizumab and has demonstrated a good safety profile.

The assay is meant to determine patient eligibility for atezolizumab, which was granted FDA approval in PD-L1-positive lung cancer on October, 15. The assay was used in the IMpower010 study.

Atezolizumab is now approved for the adjuvant treatment of NCSLC expressing PD-L1≥1%. The approval is based on the IMpower010 study.

The breakthrough therapy designation marks the agents seventh regulatory designation.

Genomic and biomarker testing is increasing at OneOncology community cancer centers across a number of tumor types.

According to early clinical trial results, taletrectinib can induce responses in patients with ROS1-positive non–small cell lung cancer.

In patients with KRAS-mutant non–small cell lung cancer, treatment with rigosertib in combination with nivolumab showed promising signals of efficacy and safety.

Sotorasib leads to intracranial responses in patients with KRAS G12C-mutated non–small cell lung cancer, according to an update from CodeBreaK 100.

Treatment with amivantamab-vmjw in the phase 1 CHRYSALIS study has released anti-tumor activity in patients with non-small cell lung cancer harboring MET exon 14 skipping mutations treated with the agent.

During a Targeted Oncology Case-Based Roundtable event, Harry Harper, MD, discussed treatment approaches for a 68-year-old patient with RET-mutated non–small cell lung cancer.

A phase 1b trial is currently recruiting patients with advanced p53-mutated non­–small cell lung cancer in order to determine the safety and efficacy of ALRN-6924, and reduce chemotherapy toxicity in this patient population.

The FDA has granted a breakthrough therapy designation from the FDA for patients with advanced non-small cell lung cancer with a KRASG12C mutation following prior systemic treatment.

In an interview with Targeted Oncology, Aaron Lisberg, MD spoke on the importance of molecular testing for patients with lung adenocarcinoma, and provided tips for choosing between immunotherapy and a tyrosine kinase inhibitor.

The FDA has granted fast track designation to bemcentinib in combination with an anti-PD-L1 agent as a potential treatment option for patients with AXL-positive advanced or metastatic non-small cell lung cancer.

Patients with previously treated non–small cell lung cancer harboring EGFR exon 20 insertion mutations showed promising preliminary anti-tumor activity and an acceptable safety profile across all of the doses tested in a phase 1 trial of CLN-081.

In the phase 1/2 ARROW study, pralsentinib was found to be well-tolerated and showed durable responses as treatment of patients with RET fusion-positive non-small cell lung cancer, including those who were not eligible for platinum-based therapy.

Joshua K. Sabari, MD, discusses the need for EGFR inhibitors designed specifically to treat patients with EGFR-mutant non–small cell lung cancer and an exon 20 insertion.

The FDA has approved Guardant360, a liquid biopsy companion diagnostic for tumor mutation profiling or comprehensive genomic profiling to identify patients with locally advanced or metastatic non-small cell lung cancer who have a KRAS G12C mutation and may benefit from sotorasib.

The FDA has granted accelerated approval to sotorasib for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer, as determined by an FDA-approved test, who have received at least one prior systemic therapy.